(Q44083749)

reason for preferred rank

29 November 2017

title

13-cis-Retinoic Acid and Interferon -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin (English)

1 reference

https://api.crossref.org/works/10.1093/JNCI/84.4.235

11 November 2022

13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

main subject

squamous cell carcinoma

1 reference

1 reference

https://api.crossref.org/works/10.1093/JNCI/84.4.235

11 November 2022

1

S. M. Lippman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

author name string

D. R. Parkinson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

L. M. Itri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

R. S. Weber

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

S. P. Schantz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

D. M. Ota

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

M. A. Schusterman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

I. H. Krakoff

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

J. U. Gutterman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

W. K. Hong

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1734084

11 November 2022

language of work or name

English

0 references

publication date

1 February 1992

1 reference

29 November 2017

19 February 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1734084

full work available at URL

11 November 2022

http://academic.oup.com/jnci/article-pdf/84/4/235/7805740/84-4-235.pdf

file format

Portable Document Format

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1093/JNCI/84.4.235

Journal of the National Cancer Institute

11 November 2022

published in

1 reference

29 November 2017

volume

84

1 reference

29 November 2017

issue

4

1 reference

29 November 2017

page(s)

235-241

1 reference

29 November 2017

Identifiers

DOI

1 reference

29 November 2017

1 reference